Barry Rosenbloom is an Oncology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 78 publications with 4,650 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9090 Wilshire Blvd
Ste 200
Beverly Hills, CA 902111850
Telephone
310-888-8680Registry record last updated 30 Apr 2008.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20256 payments
- SANOFI US SERVICES INC.Program year20251 payment
- GENZYME CORPORATIONProgram year202412 payments$12,025openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
23.8%Benzodiazepine10.4%Lorazepam42%Diazepam22%Alprazolam21%Clonazepam15%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator3.6%Zolpidem Tartrate88%Zolpidem Tartrate Er12%Part D<11 patients+ 9 more classes in this area
Cancer & immunology
19.3%Kinase inhibitor8.6%Imbruvica42%Jakafi25%Calquence8%Tagrisso7%Bosulif6%Gleevec6%Ibrance6%Part D<11 patientsAromatase Inhibitor4.6%Letrozole90%Exemestane10%Part D<11 patients+ 6 more classes in this area
Cardiovascular
16%Statin5.3%Atorvastatin Calcium53%Rosuvastatin Calcium38%Livalo9%Part D<11 patientsCalcium channel blocker2.9%Amlodipine Besylate100%Part D≥11 patients+ 8 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Challenges in Gaucher disease: Perspectives from an expert panel
Molecular Genetics and Metabolism
2025 - Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
American Journal of Hematology
2022 - Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
Molecular Genetics and Metabolism
2020 - Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease
Molecular Genetics and Metabolism Reports
2020 - Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Blood Cells Molecules and Diseases
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”